Andre Goy, MD
Chimeric antigen receptor (CAR) T-cell therapies have been commercially available for less than 2 years. In that short time, they have fundamentally improved the prognosis for many patients with lymphoma and leukemia. Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending CAR T-cell therapies to the outpatient setting.
Table. Oncologists' Perceptions About Toxicity and Management of CAR T-cell Therapy
AE indicates adverse effects; CAR, chimeric antigen receptor.
... to read the full story